Number of Transfusions

Since its commercialisation, Cerus has sold kits to produce more than 6,500,000 INTERCEPT™ platelet units, and is in routine use in more than 30 countries and more than 230 blood centres around the world.

The INTERCEPT Blood System is the pathogen inactivation system of choice in five countries (Switzerland, Belgium, Iceland, Slovenia and Kuwait) where 100% of produced platelets units are treated.

Major blood collection organisations across the world have chosen the INTERCEPT Blood System for platelets as their pathogen inactivation system of choice. Here are some recent examples:

• Cerus and the Swiss Red Cross Renew Commercial Contract with a Five-Year National Purchase Agreement for the INTERCEPT Blood System for Platelets
• Cerus Signs INTERCEPT Platelet Agreement with Sweden’s Largest Blood Product Supplier
• Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma
• Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology